Article

Objectives : To follow-up on the changes in lung function and lung radiographic pictures of severe acute respiratory syndrome (SARS) patients discharged from Xiaotangshan Hospital in Beijing (by regularly receiving examination), and to analyze retrospectively the treatment strategy in these patients. Methods: Surviving SARS patients were seen at least twice within 3 months after discharge and underwent SARS-associated coronavirus (SARS-CoV) IgG antibody testing, pulmonary function testing, and chest radiography and/or high-resolution CT (HRCT) examinations at Chinese PLA General Hospital. The treatments received at Xiaotangshan Hospital were analyzed retrospectively and were correlated to later status. Results: Positive SARS-Co virus IgG antibody results were seen in 208 of 258 patients, with 21.3 % (55 of 258 patients) still having a pulmonary diffusion abnormality (DLCO < 80 % of predicted). By comparing the 155 survivors with positive SARS-CoV IgG antibody results and DLCO < 80 % predicted with the 50 patients with negative SARS-CoV IgG results, we found that 53 patients with positive SARS-CoV IgG results and a lung diffusion abnormality had endured a much longer course of fever and received larger doses of glucocorticoid, as well as higher ratios of oxygen inhalation and noninvasive ventilation treatment. For these patients, 51 of 53 patients with positive SARS-CoV IgG results and a lung diffusion abnormality underwent pulmonary function testing after approximately 1 month. DLCO improved in 80.4 % of patients (41 of 51 patients). Of the patients with a lung diffusion abnormality, 40 of 51 patients showed lung fibrotic changes in the lung image examination and 22 patients (55 %) showed improvement in lung fibrotic changes 1 month later. Conclusion: These findings suggest that lung fibrotic changes caused by SARS disease occurred mostly in severely sick patients and may be self-rehabilitated. DLCO scores might be more sensitive than HRCT when evaluating lung fibrotic changes.

Langue : ANGLAIS

Tiré à part : OUI